Carla Bruni Completes Breast Cancer Treatment, Highlights Importance of Screening and Advances in Hormone Therapy
Published: December 21, 2023 (Updated: December 22, 2023)
Primary Keyword: Breast cancer Hormone Therapy
Primary Topic: Updates on breast cancer treatment, specifically hormone therapy, and the importance of early detection.
Secondary keywords: Breast cancer screening, metastatic breast cancer, estrogen receptor mutations, cancer relapse, hormone therapy side effects, cancer treatment advances, Carla Bruni, breast cancer awareness.
French singer and former First Lady Carla Bruni has announced the completion of her hormone therapy following a breast cancer diagnosis received in late 2019. Bruni shared the news on her Instagram account on December 20,2023,expressing profound gratitude for scientific advancements and the dedication of her medical team. Her announcement also served as a renewed call to action for women to prioritize annual breast cancer screenings.
Bruni publicly revealed her diagnosis in October 2023, having privately undergone treatment for four years. She emphasized the effectiveness of hormone therapy, despite acknowledging its challenging side effects, stating it provides crucial protection against relapse – a significant concern in the years following an initial diagnosis.”Despite its fairly aggressive side effects, I am grateful to science for having invented hormone therapy: it effectively protects against relapse which is frequent in the years following diagnosis,” Bruni wrote.
Understanding Hormone Therapy in Breast Cancer Treatment
Hormone therapy is a cornerstone of treatment for hormone receptor-positive breast cancers, which represent a significant proportion of all breast cancer diagnoses. These cancers rely on hormones, specifically estrogen, to fuel their growth.Hormone therapy works by either blocking the body’s ability to produce estrogen or by preventing estrogen from attaching to cancer cells. Common types of hormone therapy include selective estrogen receptor modulators (SERMs) like tamoxifen, aromatase inhibitors (AIs) like letrozole and anastrozole, and ovarian suppression therapy.
While highly effective for many patients, hormone therapy isn’t universally successful. A growing body of research highlights a critical challenge: the growth of mutations in the estrogen receptor (ER) gene in approximately 30-40% of patients with advanced, hormone receptor-positive breast cancer. These mutations can render hormone therapy ineffective, leading to disease progression and relapse.
The Challenge of Estrogen Receptor Mutations and Future directions
Detecting these ER mutations early is now a major focus of cancer research. Liquid biopsies – blood tests that analyze circulating tumor DNA – offer a promising avenue for identifying these mutations before the cancer significantly progresses. This allows oncologists to proactively adjust treatment plans, often combining hormone therapy with other therapies like CDK4/6 inhibitors (which block cell cycle progression) to overcome resistance and improve outcomes.
“The current challenge is to detect these mutations early in the blood, before the cancer progresses, to adapt hormonal treatment, combine it with cell cycle inhibitors and thus reduce the risk of tumor re-evolution,” explains Dr. Sara Hurvitz, a leading breast oncologist at UCLA, in a recent interview with Cancer Therapy Advisor. (source: https://www.cancertherapyadvisor.com/view/liquid-biopsies-for-er-mutations-in-metastatic-breast-cancer)
The Importance of regular Screening
Bruni’s public advocacy underscores the vital importance of regular breast cancer screening. Early detection significantly improves treatment outcomes and survival rates. Guidelines vary, but generally, women should discuss with their healthcare provider when to begin screening mammograms, typically starting between ages 40 and 50, depending on individual risk factors.
Bruni’s message is clear: “I want to say once again to all the women
Worth a look